Fonda Allen Jill, Stoll Katie, Bernhardt Barbara A
Department of Obstetrics and Gynecology, The George Washington University, 2150 Pennsylvania Ave, NW Washington, DC 20037.
Genetic Support Foundation, Olympia, WA; Providence Health & Services, Olympia, WA.
Semin Perinatol. 2016 Feb;40(1):44-55. doi: 10.1053/j.semperi.2015.11.007. Epub 2015 Dec 21.
Genetic carrier screening, prenatal screening for aneuploidy, and prenatal diagnostic testing have expanded dramatically over the past 2 decades. Driven in part by powerful market forces, new complex testing modalities have become available after limited clinical research. The responsibility for offering these tests lies primarily on the obstetrical care provider and has become more burdensome as the number of testing options expands. Genetic testing in pregnancy is optional, and decisions about undergoing tests, as well as follow-up testing, should be informed and based on individual patients' values and needs. Careful pre- and post-test counseling is central to supporting informed decision-making. This article explores three areas of technical expansion in genetic testing: expanded carrier screening, non-invasive prenatal screening for fetal aneuploidies using cell-free DNA, and diagnostic testing using fetal chromosomal microarray testing, and provides insights aimed at enabling the obstetrical practitioner to better support patients considering these tests.
在过去20年里,基因携带者筛查、非整倍体产前筛查和产前诊断检测有了显著扩展。部分受强大市场力量推动,新的复杂检测方式在有限的临床研究后问世。提供这些检测的责任主要落在产科护理提供者身上,且随着检测选项数量的增加,这一责任变得更加繁重。孕期基因检测是可选择的,关于是否接受检测以及后续检测的决定应基于充分了解并依据个体患者的价值观和需求做出。仔细的检测前和检测后咨询对于支持明智的决策至关重要。本文探讨了基因检测技术扩展的三个领域:扩展携带者筛查、使用游离DNA进行胎儿非整倍体的无创产前筛查以及使用胎儿染色体微阵列检测进行诊断检测,并提供相关见解,旨在使产科从业者能够更好地支持考虑进行这些检测的患者。